UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The Lancet (British edition), ISSN 0140-6736, 11/2017, Volume 390, Issue 10109, pp. 2266 - 2277
BREAST-CANCER | BLADDER-CANCER | LUNG-CANCER | 2ND-LINE THERAPY | TRANSITIONAL-CELL-CARCINOMA | FOLLOW-UP | OPEN-LABEL | FACTOR RECEPTOR-2 | II TRIAL | ENDOTHELIAL GROWTH-FACTOR | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Carcinoma, Transitional Cell - mortality | Prognosis | Humans | Middle Aged | Male | Neoplasm Invasiveness - pathology | Urinary Bladder Neoplasms - pathology | Adult | Female | Urinary Bladder Neoplasms - mortality | Double-Blind Method | Risk Assessment | Docetaxel | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Carcinoma, Transitional Cell - pathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Neoadjuvant Therapy - methods | Carcinoma, Transitional Cell - drug therapy | Survival Analysis | Aged | Neoplasm Staging | Antimitotic agents | Care and treatment | Carcinoma | Analysis | Clinical trials | Product development | Metastasis | Antineoplastic agents | Cancer | Cytotoxicity | Oncology | Patients | Cancer therapies | Evidence-based medicine | Metastases | Angiogenesis | Chemotherapy | Platinum | Medical prognosis | Ligands | Clinical medicine | Urothelial carcinoma | Vascular endothelial growth factor | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10031, pp. 1909 - 1920
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Immunoglobulins, Intravenous - administration & dosage | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - administration & dosage | Cisplatin - administration & dosage | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Urologic Neoplasms - drug therapy | Urologic Neoplasms - genetics | Aged, 80 and over | Adult | Female | Drug Administration Schedule | Carboplatin - administration & dosage | Treatment Outcome | Mutation - genetics | B7-H1 Antigen - immunology | Disease Progression | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Infusions, Intravenous | Medical colleges | Care and treatment | Chemotherapy | Carcinoma | Clinical trials | Monoclonal antibodies | Metastasis | Research institutes | Cancer | Analysis | Immunotherapy | Medical prognosis | Ligands | Genomes | Mutation | Gene expression | Cancer therapies | Bladder cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 09/2011, Volume 121, Issue 9, pp. 3609 - 3622
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Mammary Glands, Human - cytology | Self Tolerance - immunology | Breast Neoplasms - immunology | Neoplasm Invasiveness | Humans | Middle Aged | Tumor Microenvironment | Receptors, Natural Killer Cell - immunology | Disease Progression | Killer Cells, Natural - cytology | Animals | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Interferon-gamma - immunology | K562 Cells | Killer Cells, Natural - immunology | Female | Mammary Glands, Human - physiology | Tumor Cells, Cultured | Cytotoxicity, Immunologic - immunology | Receptors, Natural Killer Cell - genetics | Development and progression | Killer cells | Genetic aspects | Breast cancer | Cellular immunity | Cancer cells | Index Medicus | Abridged Index Medicus | Life Sciences | Immunology | Immunotherapy | Cancer
Journal Article
4.
Full Text
Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex
Science (American Association for the Advancement of Science), ISSN 0036-8075, 03/2017, Volume 355, Issue 6331, pp. 1306 - 1311
Cricetulus | Signal Transduction | TOR Serine-Threonine Kinases - metabolism | Cholesterol, HDL - metabolism | Humans | Nuclear Proteins - metabolism | Cholesterol - metabolism | Amino Acid Transport Systems - metabolism | Amino Acid Motifs | Mechanistic Target of Rapamycin Complex 1 | Multiprotein Complexes - antagonists & inhibitors | TOR Serine-Threonine Kinases - antagonists & inhibitors | Multiprotein Complexes - metabolism | Animals | Carrier Proteins - metabolism | Lysosomes - metabolism | Biological Transport | HEK293 Cells | Amino Acid Transport Systems - genetics | Fibroblasts | Mice | Enzyme Activation | Mutation | CHO Cells | TOR protein | Niemann-Pick disease | Diabetes mellitus | Lipids | Amino acids | Rapamycin | Metabolism | Kinases | Cholesterol | Proteins | Diet | Sterols | Arginine | Protein kinase | Nutrients | Npc1 protein | Protein transport | Cancer | Index Medicus | Lysosomes | Activation | Transporter
Journal Article
Cancer and metastasis reviews, ISSN 0167-7659, 3/2011, Volume 30, Issue S1, pp. 3 - 7
Molecular imaging | GEP-NETs | TNM staging | Biomedicine | Biomarkers | Oncology | Cancer Research | Neuroendocrine tumor | WHO classification | Biomedicine general | Life Sciences & Biomedicine | Science & Technology | Neuroendocrine Tumors - pathology | Neuroendocrine Tumors - classification | Humans | Molecular Imaging | Neuroendocrine Tumors - diagnosis | Neoplasm Staging | Biomarkers, Tumor | Diagnosis | PET imaging | Histochemistry | Public health | Cancer | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 06/2020, Volume 395, Issue 10241, pp. 1907 - 1918
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cancer patients | Research | Oncology, Experimental | Cancer | Pandemics | Laboratories | Identification methods | Health services | Viral diseases | Sex | Azithromycin | Oncology | Infections | Malignancy | Cancer therapies | Risk factors | Consortia | COVID-19 | Variables | Databases | Surgery | Remission | Population | Diagnosis | Age | Obesity | Ventilators | Data analysis | Statistical analysis | Hematology | Mortality | Medical treatment | Severe acute respiratory syndrome | Regression analysis | Coronaviruses | Risk analysis | Minority & ethnic groups | Patients | Cancer surgery | Severe acute respiratory syndrome coronavirus 2 | Ethnicity | Hydroxychloroquine | Data collection | Breast | Prostate | Smoking | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1263 - 1268
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prednisolone - administration & dosage | Prognosis | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - mortality | Prostatic Neoplasms, Castration-Resistant - pathology | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Drug Therapy, Combination | Drug Administration Schedule | Administration, Oral | Kaplan-Meier Estimate | Androstenes | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Disease Progression | Prostate-Specific Antigen - blood | Disease-Free Survival | Survival Analysis | Aged | Androstenols - administration & dosage | Prostatic Neoplasms, Castration-Resistant - mortality | Androgen Antagonists - administration & dosage | Neoplasm Staging | Care and treatment | Chemotherapy | Corticosteroids | Hospitals | Analysis | Prednisone | Metastasis | Prostate cancer | Cancer | Index Medicus
Journal Article